Could cause temporary or reversible harm; serious harm is unlikely.
Failed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit
| Brand name | GRANIX |
| Generic name | TBO-FILGRASTIM |
| Active ingredient(s) | FILGRASTIM |
| Distributed by / for | Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel |
| NDC | 63459-910-11 |
| Full product label | Granix (tbo-filgrastim) Injection 300 mcg/0.5 mL, Single Dose prefilled syringe, packaged as a) 1 syringe in 1 CARTON, NDC 63459-910-11, Blister NDC 63459-910-12; (b)10 syringes in 1 CARTON, NDC 63459-910-15, Blister NDC 63459-910-12; (c) 1 syringe in 1 CARTON, NDC 63459-910-17 without safety guard and blister, Rx Only, Manufactured by: UAB Teva Baltics, Vilnius, Lithuania. Distributed by Teva Pharmaceuticals USA, Inc. North Wales PA 19454. Product of Israel. |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Distribution | Product was distributed nationwide. |
| Quantity | 34,636 cartons |
| Recall initiated | 2025-01-10 |
| Report date | 2025-02-12 |
| Recall completed | — |
| Recall number | D-0218-2025 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗